Update in Chronic Obstructive Pulmonary Disease 2014

Seemungal, Terence; Wedzicha, Jadwiga A.

doi:10.1164/rccm.201503-0534up

Cited by 8 publications

(5 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While death rates from heart disease and stroke are declining, the death rate from COPD has doubled since 1970 [4]. The course of COPD is characterized by intermittent worsening of symptoms called exacerbations [6–10]. Approximately half of exacerbations are caused by bacterial infection [6].…”

Section: Chronic Obstructive Pulmonary Diseasementioning

confidence: 99%

Potential impact of a Moraxella catarrhalis vaccine in COPD

Perez

Murphy

2019

Vaccine

View full text Add to dashboard Cite

Moraxella catarrhalis is the second most common cause of exacerbations in adults with COPD, resulting in enormous morbidity and mortality in this clinical setting. Vaccine development for M. catarrhalis has lagged behind the other two important causes of exacerbations in COPD, nontypeable Haemophilus influenzae and Streptococcus pneumoniae. While no licensed vaccine is currently available for M. catarrhalis, several promising candidate vaccine antigens have been identified and characterized and are close to entering clinical trials. Key steps that are required to advance vaccines for M. catarrhalis along the translational pipeline include standardization of assay systems to assess candidate antigens, identification of a reliable correlate of protection and expansion of partnerships between industry, academia and government to overcome regulatory hurdles. A vaccine to prevent M. catarrhalis infections in COPD would have a major impact in reducing morbidity, mortality and healthcare costs in COPD.

show abstract

Section: Chronic Obstructive Pulmonary Diseasementioning

confidence: 99%

Potential impact of a Moraxella catarrhalis vaccine in COPD

Perez

Murphy

2019

Vaccine

View full text Add to dashboard Cite

show abstract

“…Based on the underlying pathophysiological mechanisms of emphysema, several potential therapeutic approaches targeting the chronic inflammation and subsequent repair have been discussed [13]. Indeed, new strategies for the treatment of COPD focus on the development of anti-inflammatory drugs, including antagonists of cytokines such as tumor necrosis factor (TNF)-α [14] and interleukin (IL)-8 [15].…”

Section: Introductionmentioning

confidence: 99%

Protective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 production

et al. 2017

View full text Add to dashboard Cite

PurposeChronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow obstruction and pulmonary emphysema. Persistent inflammation and remodeling of the lungs and airways result in reduced lung function and a lower quality of life. Galectin (Gal)-9 plays a crucial role as an immune modulator in various diseases. However, its role in the pathogenesis of pulmonary emphysema is unknown. This study investigates whether Gal-9 is involved in pulmonary inflammation and changes in emphysema in a porcine pancreatic elastase (PPE)-induced emphysema model.Materials and methodsGal-9 was administered to mice subcutaneously once daily from 1 day before PPE instillation to day 5. During the development of emphysema, lung tissue and bronchoalveolar lavage fluid (BALF) were collected. Histological and cytological findings, concentrations of chemokines and matrix metalloproteinases (MMPs) in the BALF, and the influence of Gal-9 treatment on neutrophils were analyzed.ResultsGal-9 suppressed the pathological changes of PPE-induced emphysema. The mean linear intercept (Lm) of Gal-9-treated emphysema mice was significantly lower than that of PBS-treated emphysema mice (66.1 ± 3.3 μm vs. 118.8 ± 14.8 μm, respectively; p < 0.01). Gal-9 decreased the number of neutrophils and levels of MMP-9, MMP-2 and tissue inhibitor of metalloproteinases (TIMP)-1 in the BALF. The number of neutrophils in the BALF correlated significantly with MMPs levels. Interestingly, Gal-9 pretreatment in vitro inhibited the chemotactic activity of neutrophils and MMP-9 production from neutrophils. Furthermore, in Gal-9-deficient mice, PPE-induced emphysema progressed significantly compared with that in wild–type (WT) mice (108.7 ± 6.58 μm vs. 77.19 ± 6.97 μm, respectively; p < 0.01).ConclusionsThese results suggest that Gal-9 protects PPE-induced inflammation and emphysema by inhibiting the infiltration of neutrophils and decreasing MMPs levels. Exogenous Gal-9 could be a potential therapeutic agent for COPD.

show abstract

“…In einer aktuellen Übersichtsarbeit wurde dargestellt, wie häufig sich nach der alten ICD-9 klassifizierte pulmonale Erkrankungen überlappen [15]. Die gut 900 Patienten wurden folgenden Kategorien zugeordnet: nicht näher bezeichnete chronische Atemwegsobstruktion (n = 815), chronische Bronchitis (n = 309), Emphysem (n = 231) oder nicht näher bezeichnete chronische Bronchitis (n = 214).…”

Section: Original-und üBersichtsarbeiten Zur Chronischen Bronchitisunclassified

Expertentreffen COPD: Personalisierte Therapie der COPD – Wunsch oder Wirklichkeit?

et al. 2016

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is considered to be a complex and heterogeneous disease comprising multiple components. Its clinical presentation, pattern of functional disturbance, disease presentation and pathology varies tremendously between individuals despite the common feature of incompletely reversible airflow obstruction. It is therefore widely accepted that COPD is characterized by discriminable phenotypes that represent specific patterns of these disease features. COPD phenotypes are believed to correlate with outcome parameters such as severity of symptoms, exacerbations, functional loss or death and to require different treatment algorithms.This survey is the result of presentations that were given during an expert conference. It highlights the significance of major comorbidities, genetic, morphologic and inflammatory COPD-phenotypes and their impact on disease progression and treatment modalities.

show abstract

Update in Chronic Obstructive Pulmonary Disease 2014

Cited by 8 publications

References 89 publications

Potential impact of a Moraxella catarrhalis vaccine in COPD

Potential impact of a Moraxella catarrhalis vaccine in COPD

Protective effect of Galectin-9 in murine model of lung emphysema: Involvement of neutrophil migration and MMP-9 production

Expertentreffen COPD: Personalisierte Therapie der COPD – Wunsch oder Wirklichkeit?

Contact Info

Product

Resources

About